Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Lale Ozcan
Columbia University Health Sciences, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tabomedex Biosciences
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Ozcan is co-founder of a startup company called Tabomedex Biosciences, and holds equity in this non-public company. Columbia has determined that the company’s aims (including development of MK2 inhibitors for treatment of diabetes) are related to the research in this R01; that the outcome of this research could affect the company or Dr. Ozcan’s significant financial interest in the company; and that the design, conduct, and/or reporting of this research could be affected by this financial interest.
CaMKII/MK2 Signaling in Cardiometabolic Disease
Project Narrative The marked increase in cardiovascular disease (CVD) in patients with type 2 diabetes (T2D) demands an integrated approach to cardiometabolic disease. In this context, the overall objective of this project is to investigate the mechanisms and consequences of a common upstream signaling pathway in hepatocytes and macrophages in metabolism and atherosclerosis, respectively, and to explore its therapeutic potential. Successful completion of this proposal will offer new mechanistic insight and potential therapeutic targets related to the integrated problem of cardiometabolic disease, which represents a deadly and expanding epidemic.
Filed on February 20, 2018.
Tell us what you know about Lale Ozcan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Lale Ozcan”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Lale Ozcan | Columbia University Health Sciences | Conflict of Interest | Tabomedex Biosciences | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.